DaVita (DVA) to Release Earnings on Tuesday

DaVita (NYSE:DVA) will likely be releasing its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect DaVita to post earnings of $2.33 per share and revenue of $3.3564 billion for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 5, 2026 at 5:00 PM ET.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Monday, February 2nd. The company reported $3.40 EPS for the quarter, topping the consensus estimate of $3.24 by $0.16. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The business had revenue of $3.62 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same quarter in the previous year, the firm posted $2.24 earnings per share. DaVita’s quarterly revenue was up 9.9% on a year-over-year basis. On average, analysts expect DaVita to post $14 EPS for the current fiscal year and $17 EPS for the next fiscal year.

DaVita Stock Up 1.7%

Shares of NYSE DVA traded up $2.58 on Monday, reaching $154.23. 289,492 shares of the company’s stock traded hands, compared to its average volume of 964,921. The business’s 50 day simple moving average is $151.18 and its two-hundred day simple moving average is $131.51. DaVita has a 12 month low of $101.00 and a 12 month high of $159.42. The company has a market cap of $10.30 billion, a price-to-earnings ratio of 15.60, a price-to-earnings-growth ratio of 0.53 and a beta of 0.84.

Institutional Investors Weigh In On DaVita

Several large investors have recently added to or reduced their stakes in the stock. Caitlin John LLC purchased a new stake in shares of DaVita during the 4th quarter worth $34,000. Canada Pension Plan Investment Board purchased a new stake in shares of DaVita during the second quarter valued at about $43,000. Kestra Advisory Services LLC bought a new stake in shares of DaVita in the 4th quarter valued at about $45,000. iSAM Funds UK Ltd bought a new position in shares of DaVita during the 3rd quarter worth approximately $46,000. Finally, AlphaCentric Advisors LLC purchased a new stake in DaVita during the fourth quarter valued at approximately $50,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DVA has been the subject of a number of analyst reports. Barclays raised their price objective on DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 3rd. TD Cowen restated a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. UBS Group lifted their price target on DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research report on Wednesday, February 4th. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, Zacks Research downgraded shares of DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. One equities research analyst has rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $155.80.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.